Comment on "Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry"

Dig Liver Dis. 2023 Sep;55(9):1304. doi: 10.1016/j.dld.2023.03.012. Epub 2023 Apr 14.

Authors

Sofia Ridolfo¹, Angelica Toppeta², Alessandra Dell'Era³, Sandro Ardizzone²

Affiliations

¹ Department of Gastroenterology, Luigi Sacco Hospital, University of Milan, Milan, Italy. Electronic address: sofia.ridolfo@unimi.it.
² Department of Gastroenterology, Luigi Sacco Hospital, University of Milan, Milan, Italy.
³ Department of Gastroenterology, Luigi Sacco Hospital, University of Milan, Milan, Italy; Department of Biomedical and Clinical Sciences, Luigi Sacco, University of Milan, Milan, Italy.

PMID: 37062627
DOI: 10.1016/j.dld.2023.03.012

No abstract available

Keywords: Crohn's disease; Endoscopic postoperative recurrence; Ustekinumab.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Crohn Disease* / drug therapy
Crohn Disease* / surgery
Humans
Registries
Ustekinumab*

Substances

Ustekinumab
vedolizumab
Antibodies, Monoclonal, Humanized